Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOEX.L Regulatory News (OEX)

  • There is currently no data for OEX

Update on Underwritten Rights Issue

3 Aug 2015 07:51

RNS Number : 8422U
Oilex Ltd
03 August 2015
 



ASX Announcement

 

3 August 2015

 

 

ASX: OEX

AIM: OEX

 

Update on Underwritten Rights Issue

 

Oilex Ltd (Oilex or the Company) is pleased to provide an update on the result of the previously announced Underwritten Rights Issue, and announces changes to the second tranche of the previously announced Placing.

 

As announced on 31 July 2015, 16,235,098 Rights Issue Shares have been taken up by shareholders, resulting in a shortfall in the Rights Issue of 153,241,412 shares. Under the terms of the underwriting agreement in respect of the Rights Issue, and as disclosed in the Company's announcement of 17 July 2015 (paragraph 5.7 of the Offer Booklet), as the share price of Oilex has, during the offer period, fallen below the A$0.041 Rights Issue offer price, a potential termination event has been triggered whereby the underwriter has the right to terminate the underwriting agreement.

 

In light of this development, the Company has taken steps to seek alternative participants for part of the Rights Issue shortfall. Accordingly, Zeta Resources Ltd (Zeta) has agreed to take up 62,011,067 shares by way of placement out of the Rights Issue shortfall at the Offer Price of A$0.041, for a total consideration of approximately A$2.55 million (£1.24 million, US$1.95 million) and will receive a fee of 6% that would otherwise have been paid to the underwriter. On this basis, the underwriter has agreed not to invoke its termination right under the underwriting agreement, and the underwriter (or its nominees) will take up the remaining Rights Issue shortfall.

 

As announced on 7 and 8 July 2015, Zeta's participation in the second tranche of the Placing will be settled in 2 tranches. As a result of Zeta's take up of Rights Issue shortfall shares as outlined above, and in order that it and its associates do not breach relevant Australian takeovers laws (under which, broadly, a person may not acquire shares if that would cause their and their associates' voting power to exceed 20%), Zeta has agreed that its second tranche investment will now proceed as follows (subject to approval of the resolutions proposed at the Company's General Meeting convened for 12 August 2015):

· 50,000,000 new ordinary shares will be placed with Zeta at a price of A$0.041 (2 pence) per share, to be settled immediately following the General Meeting;

· a further 124,019,608 (previously 225,490,196) new ordinary shares will be placed with Zeta at a price of A$0.0418 (2.04 pence) per share, to be settled by no later than 12 November 2015. These shares will be issued out of the authorisation to be sought at the General Meeting (covering 225,490,196 shares); and

· in lieu of the remaining shares originally envisaged to be issued to Zeta, (being 101,470,588 shares) the Company will issue A$4,243,500 (approximately £2.07 million) of 20 year, zero coupon unsecured convertible loan notes to Zeta, which will be convertible into shares at Zeta's option at any time, subject to compliance with Australian law, at a conversion price of A$0.0418 per share. The issue of these convertible notes will occur contemporaneously with the issue to Zeta of the 124,019,608 new ordinary shares referred to above. These convertible notes will be issued pursuant to the Company's placement capacity under Listing Rule 7.1 (as refreshed at the General Meeting). To the extent that the convertible notes are not converted, they will be redeemable on 30 June 2035 or such later date as agreed with Zeta. The Zeta Convertible Notes will have the right to participate in rights issues and other pro-rata issues on an "as converted" basis, subject to compliance with law.

 

 

Upon completion of the Rights Issue and Tranche 2 placing, Zeta and associates will hold approximately 275 million ordinary shares, representing approximately 19.6% of the Company's enlarged share capital (on an undiluted basis). Zeta will also hold A$4,243,500 of unsecured convertible notes, convertible into 101,470,588 ordinary shares.

 

The remaining portion of the second tranche of the Placing will proceed as previously announced and the Placing timetable remains unchanged. Given their relevance to the matters to be considered at the General Meeting, shareholders will be notified of the above changes by letter in the coming days.

 

 Managing Director of Oilex, Ron Miller, said;

"The financial support by Zeta not only in the second tranche, but now the Rights Issue shortfall is very pleasing and demonstrates their commitment to Oilex's business plan. This plan is focussed on production and cashflow from the recently independently assessed Reserves at our Cambay Field in India. We are delighted that the Rights Issue will successfully complete, leading to a General Meeting on 12 August 2015 where shareholders will have the opportunity to approve the second tranche of the Placing."

 

 

 

Yours faithfully,

  

Ron Miller

Managing Director

 

For further information, please contact the company or its advisors listed below:

 

PAC Partners Pty Ltd

Australian Broker

Andrew Shearer

Email: ashearer@pacpartners.com.au

Tel: +61 3 8633 9862

Australia

Westhouse Securities Limited

AIM Broker

Robert Finlay / Alastair Stratton

Email:  alastair.stratton@westhousesecurities.com

Tel: +44 20 7601 6100

UK

 

Strand Hanson Limited

Nominated Adviser

Rory Murphy /Ritchie Balmer

Email:  

oilex@strandhanson.co.uk

Tel: +44 20 7409 3494

UK

 

Vigo Communications

Public Relations UK

Patrick d'Ancona / Chris McMahon

Email:patrick.dancona@vigocomms.com

chris.mcmahon@vigocomms.com

Tel: +44 20 7016 9570

UK

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSRTAIVIIE
Date   Source Headline
7th Aug 20209:32 amRNSTermination of JPDA Arbitration Proceedings
31st Jul 202011:07 amRNSJune 2020 Quarterly Report
31st Jul 202010:45 amRNSLoan Restructure and Equity Issue
30th Jul 20209:00 amRNSManaging Director Contract Extension
27th Jul 20207:00 amRNSWest Kampar Update
17th Jul 20207:07 amRNSIssue of Securities
30th Jun 202010:40 amRNSSuccessful Bid for Cooper Basin Permit
30th Jun 20208:17 amRNSResults of General Meeting
30th Jun 20208:11 amRNSExecutive Director Contract Extension
30th Jun 20208:05 amRNSChange of Registered Office
29th Jun 20207:00 amRNSIndia Update
15th Jun 202010:28 amRNSChange to Notice of Meeting
15th Jun 20207:56 amRNSArmour Share Purchase Agreement
5th Jun 202011:52 amRNSExtension to Armour Agreement
3rd Jun 20201:14 pmRNSNotice of Change of Interest of Substantial Holder
1st Jun 20207:15 amRNSExtension to Armour Agreement
29th May 20207:00 amRNSNotice of General Meeting
27th May 20209:28 amRNSSale of Cooper Eromanga Basin Assets
26th May 20207:00 amRNSNotice of Change of Interest of Substantial Holder
15th May 20207:00 amRNSIssue of Securities
6th May 20207:00 amRNSAppendix 3Z B Lingo
6th May 20207:00 amRNSReplacement Appendix 5B
5th May 20208:36 amRNSBoard Changes
30th Apr 20209:16 amRNSMarch 2020 Quarterly Report
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 202011:02 amRNSCooper Basin Update
27th Apr 20207:14 amRNSCorrection: Variation to Financing Terms
23rd Apr 20201:45 pmRNSVariation to Financing Terms
3rd Apr 20207:00 amRNSChairman Consulting Contract Extension
3rd Apr 20207:00 amRNSExtension for Acquisition of Cooper Licences
26th Mar 20207:32 amRNSAppendix 3X Mark Bolton
26th Mar 20207:00 amRNSBoard and Executive Changes
24th Mar 20207:30 amRNSDoriemus Transaction - Update
16th Mar 20207:15 amRNSInterim Report 31 December 2019
16th Mar 20207:00 amRNSBusiness and Financial Restructure
12th Mar 20207:00 amRNSDoriemus Shareholders Approve Transaction
6th Mar 20207:15 amRNSOpportunity to Participate in Doriemus Offer
3rd Mar 202012:24 pmRNSUpdate on Cambay Sale Process
28th Feb 20209:29 amRNSExtension for Acquisition of Cooper Basin Licences
21st Feb 20207:30 amRNSStrong Funding Support for Cooper-Eromanga
11th Feb 20207:00 amRNSChairman Consulting Contract Extension
4th Feb 20207:00 amRNSAppendix 3B: Issue of Securities
3rd Feb 20202:23 pmRNSNew Series C Loan Facility
31st Jan 20208:17 amRNSDecember 2019 Quarterly Report
30th Jan 20207:00 amRNSDOR - Prop Acqn of Major Cooper-Eromanga Portfolio
29th Jan 202010:39 amRNSSale of Cooper Eromanga Basin Assets
28th Jan 20207:00 amRNSSale of Participating Interest in Bhandut
17th Jan 20202:05 pmRNSUpdate on Cambay Sale Process
7th Jan 20207:34 amRNSNotice of Change of Interest of Substantial Holder

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.